Clinical Trial Results:
A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis
Summary
|
|
EudraCT number |
2018-003206-58 |
Trial protocol |
FR DE ES GB IT |
Global end of trial date |
30 Nov 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Dec 2022
|
First version publication date |
16 Dec 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CNTO1959PSO3013
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03998683 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
G-PLUS: CR108611 | ||
Sponsors
|
|||
Sponsor organisation name |
Janssen-Cilag International N.V
|
||
Sponsor organisation address |
30, Turnhoutseweg, Belgium, 2340
|
||
Public contact |
Clinical Registry Group, Janssen-Cilag International N.V, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen-Cilag International N.V, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Nov 2021
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Nov 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the trial was to evaluate the efficacy of guselkumab for the treatment of palmoplantar non-pustular psoriasis.
|
||
Protection of trial subjects |
This study was conducted in accordance with the ethical principles that have their origin in the declaration of helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Sep 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 66
|
||
Country: Number of subjects enrolled |
Spain: 16
|
||
Country: Number of subjects enrolled |
France: 10
|
||
Country: Number of subjects enrolled |
United Kingdom: 8
|
||
Country: Number of subjects enrolled |
Italy: 17
|
||
Worldwide total number of subjects |
117
|
||
EEA total number of subjects |
109
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
104
|
||
From 65 to 84 years |
13
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||
Screening details |
A total of 146 subjects were screened, of whom 29 subjects were screen failures. A total of 117 subjects were enrolled and treated in this study. | ||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||
Period 1 title |
PHASE IIIB TRIAL (overall period)
|
||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||||||
Arm description |
Subjects received a single subcutaneous (SC) injection of placebo matched to guselkumab at Weeks 0, 4, and 12, and guselkumab 100 milligrams (mg) SC injections at Weeks 16, 20, 28, 36, and 44. | ||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Guselkumab
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Single SC injection of guselkumab 100 mg at Weeks 16, 20, 28, 36 and 44.
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Single SC injection of placebo matched to guselkumab at Weeks 0, 4 and 12.
|
||||||||||||||||||||||||||||||||||||
Arm title
|
Guselkumab | ||||||||||||||||||||||||||||||||||||
Arm description |
Subjects received a single subcutaneous (SC) injection of guselkumab 100 milligrams (mg) at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo injection matched to guselkumab at Week 16. | ||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Single SC injection of placebo matched to guselkumab at Week 16.
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Guselkumab
|
||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Single SC injection of guselkumab 100 mg at Weeks 0, 4, 12, 20, 28, 36 and 44.
|
||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single subcutaneous (SC) injection of placebo matched to guselkumab at Weeks 0, 4, and 12, and guselkumab 100 milligrams (mg) SC injections at Weeks 16, 20, 28, 36, and 44. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Guselkumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single subcutaneous (SC) injection of guselkumab 100 milligrams (mg) at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo injection matched to guselkumab at Week 16. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects received a single subcutaneous (SC) injection of placebo matched to guselkumab at Weeks 0, 4, and 12, and guselkumab 100 milligrams (mg) SC injections at Weeks 16, 20, 28, 36, and 44. | ||
Reporting group title |
Guselkumab
|
||
Reporting group description |
Subjects received a single subcutaneous (SC) injection of guselkumab 100 milligrams (mg) at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo injection matched to guselkumab at Week 16. |
|
|||||||||||||
End point title |
Percentage of Subjects who Achieved Palmoplantar Psoriasis Area and Severity Index (ppPASI75) Response at Week 16 | ||||||||||||
End point description |
ppPASI75 response was defined as improvement of greater than or equal to (>=) 75 percent (%) in ppPASI score from baseline. ppPASI: assessment tool based on PASI to assess severity of 3 symptoms - erythema, pustules/ induration, desquamation/ scale on palms or soles, each on a scale from 0 (none) to 4 (very severe), where higher score indicated more severe disease. Considering non-pustular palmoplantar disease, the score of pustules was set to '0' and thus the ppPASI75 total score was sum of sub-scores (erythema and desquamation) which ranged from 0 to 48, where higher score indicated more severe disease. Full analysis set included all randomised subjects who received at least 1 dose of study intervention and were analysed according to randomised treatment group, regardless of intervention they actually received.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline up to Week 16
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Guselkumab versus Placebo | ||||||||||||
Statistical analysis description |
Difference in rates between guselkumab and placebo
|
||||||||||||
Comparison groups |
Placebo v Guselkumab
|
||||||||||||
Number of subjects included in analysis |
117
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.533 [1] | ||||||||||||
Method |
Fisher exact | ||||||||||||
Parameter type |
Guselkumab&placebo:Percentage difference | ||||||||||||
Point estimate |
7.7
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-11.5 | ||||||||||||
upper limit |
24.7 | ||||||||||||
Notes [1] - The threshold for statistical significance was 0.05 level. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to Week 56
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The safety analysis set included all subjects who received one dose of study intervention and completed at least 1 follow-up safety assessment. Subjects were analysed according to the intervention they actually received.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Guselkumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Guselkumab 100 mg subcutaneous (SC) injections at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo injection at Week 16. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received placebo subcutaneous (SC) injections at Weeks 0, 4 and 12, and guselkumab 100 mg SC injections at Weeks 16, 20, 28, 36, and 44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
12 Jul 2019 |
This amendment was created to provide further clarification on the inclusion, exclusion and withdrawal criteria to provide specificity on the subjects to be included in this study. The frequency of visits for tests and data collection was changed. |
||
22 Apr 2020 |
This amendment was created to incorporate the following changes: The Coronavirus Disease 2019 (COVID-19) pandemic might have an impact on the conduct of this clinical study. In alignment with recent health authority guidance, the sponsor was providing options for study-related subject management in the event of disruption to the conduct of the study. |
||
18 Jun 2020 |
This amendment was created to incorporate the following changes: to revise the sample size of the study. In addition, a COVID-19 pandemic-related exclusion criterion was added, and the guidance for the reporting of adverse events was updated to include combination products. |
||
16 Jul 2020 |
This amendment was created to clarify that subjects who received prior systemic treatment with JAK inhibitors would be excluded from the study. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |